FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

Updates from a range of lung cancer studies

Prof Santos speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about updates from key trials in lung cancer. He goes in to detail about the latest results of these studies across a range of therapies.

FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC

On August 20, 2018, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSqNSCLC), with no EGFR or ALK genomic tumor aberrations. Pembrolizumab was previously granted accelerated approval for this indication in May 2017...

Interested in Participating in a Feasibility Study?

Sanofi Genzyme is currently looking for sites to participate in the feasibility for an upcoming Sanofi Genzyme study to assess a diagnostic protocol for individuals with unexplained splenomegaly and thrombocytopenia. This study will determine the prevalence of Gaucher Disease and Acid Sphingomyelinase Deficiency (Niemann-Pick A and B) among individuals with splenomegaly and thrombocytopenia who meet...

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

Opdivo is now the first Immuno-Oncology treatment approved for small cell lung cancer (SCLC) patients who received platinum-based chemotherapy and at least one other line of therapy Approval based on overall response rate and duration of response from the SCLC cohort of the Phase 1/2 CheckMate -032 trial 1 FRIDAY, AUGUST 17, 2018 6:59 AM EDT PRINCETON,...

FDA updates the prescribing information for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) to require the use of an FDA-approved companion diagnostic test

The FDA has updated the prescribing information for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) to require the use of an FDA-approved companion diagnostic test to determine PD-L1 levels in tumor tissue from patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible. Two different companion diagnostic tests were approved by the FDA, one for use...

Who’s Online

Profile picture of FLASCO